DealMaker on Deloitte’s Technology Fast 50™

November 8, 2023

DealMaker is excited to announce that it has been named a Company-to-Watch by the 2023 Deloitte Technology Fast 50™ program. Celebrating its 26th anniversary, the award recognizes emerging technology companies across North America.

Founded by two lawyers in the capital markets industry, DealMaker’s mission is to make online capital raising mainstream by allowing companies to raise capital digitally, from their communities. It provides a suite of technology tools including ecommerce checkouts for buying securities, stakeholder communication tools and digital marketing integrations.

DealMaker is an e-commerce-style digital platform that enables companies to easily raise capital online and market capital raises to the broader public. Co-Founders Rebecca Kacaba and Mat Goldstein came up with the idea for DealMaker in 2015 while running a startup practice in their law firm.

DealMaker's CEO, Rebecca Kacaba, credits their commitment to adaptability coupled with their ability to be forward-thinking and innovative with the company's early-stage success. Kacaba said, “As a company born from the drive to disrupt the decades-old antiquated industry of the capital markets, we fully embrace and lean into innovation and quick pivots. The motto ‘Our Business is Change’ reinforces the belief that we’re comfortable where others are not - we need to constantly live in the mindset of adaptation. Landing on Deloitte’s Companies-to-Watch list is a testament to our drive for forward-thinking innovation.”

This award win comes right after DealMaker’s second consecutive year ranking in the Top 10 of the Globe and Mail’s Report on Business Top Growing Companies, ranking this year in 6th place and last year in 3rd place.

Mat Goldstein, DealMaker’s Co-Founder and CSO, said “DealMaker is a pioneer in developing the online relationship between companies and their investors. We saw a huge pain point in the market where our clients were suffering, where the process of raising capital from investors was still paper-based, expensive, and obsolete - ripe for disruption. Our innovation in the space to digitize and simplify process solidifies us as a leader in this emerging market. To be given this honour as a Deloitte Company-to-Watch proves we are on the right track.”

The DealMaker platform allows brands to tap into fundraising solutions beyond traditional venture capital, by using the internet to help companies to turn their customers and fans into investors and shareholders. Also called Equity or Investor Crowdfunding, DealMaker’s software facilitates raising capital across a variety of offering structures, in both Canada and the US, tapping into exemptions including Reg A, Reg CF, Reg D, OM and Private Placements.

The Companies-to-Watch category is a ranking of Canadian technology companies with the potential to be future Technology Fast 50™ candidates by their revenue growth percentage over their last three years of operation.

“Congratulations to this year’s Companies-to-Watch winners,” commented Anders McKenzie, partner and national leader for the Technology Fast 50 program at Deloitte Canada. “These companies have demonstrated promising growth trajectories and an exemplary ability to seize opportunities even in the face of a challenging economic context. This sets them apart as members of an emerging cohort of tech leaders in Canada. We look forward to keeping an eye on their progress in the months and years to come."

‍

Yahoo Coverage

Monogram Case Study - DealMaker (Embed)

When VCs said no, Monogram turned to retail investors. That decision powered their rise from startup to publicly traded company—and even helped them raise an additional $13M privately after their Nasdaq debut.

The Challenge: Raising Capital on Their Terms

The Challenge: Raising on Their Terms

Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.

Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?

Control and ownership: Not only were they able to raise the capital they needed to grow the business—they did it on their own terms.
Long-term asset: They wanted to build an army of true believers who wanted to see the company succeed and would continue to reinvest over the years.
A value-add network: Raising from retail allowed Monogram to amass a waiting list of thousands of patients eager to participate in future trials.
Aligned incentives: Their mission to improve patient outcomes and build a better future for those struggling with joint pain resonated with retail investors.

The Power of Retail: Monogram's Capital Journey

Start Date	End Date	Type	Platform	Amount Raised	# Investors
3/13/19	3/31/20	A+	SeedInvest	$14,588,668	6,000
11/16/20	1/16/21	A+	StartEngine	$2,965,501	8,000
1/17/21	2/18/22	A+	StartEngine	$23,647,853	14,082
7/15/22	3/16/23	CF	DealMaker	$4,673,000	2,249
3/1/23	4/8/23	A+	Republic	$232,275	120
3/1/23	5/23/23	A+	DealMaker	$15,958,364	5,198
5/18/23	-	Nasdaq listing
7/24	10/24	Unit Offering	DealMaker	$12,990,103	2,745

Monogram Capital Raise Timeline

Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.

Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.

$80M+

Raised across seven campaigns

~40,000

Investors championing Monogram's vision

20%

Of each raise came from previous investors

Marketing Excellence

DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.

Premium Publications

Targeted campaigns in premium publications like Morning Brew captured qualified investors

High-Engagement Webinars

Engaging events that generated over $4.3 million in investments

Community Building

Strategic approaches that fostered a loyal shareholder base

Investment Momentum

Innovative approaches that amplified investment momentum

Monogram's Journey to Success

Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:

Filed its first patent application in 2017
Conducted clinical studies at UCLA and University of Nebraska
Expanded the team with key hires
Attracted a top-tier advisory board to guide clinical innovations
Signed their first distribution partnerships
Made headlines with cutting-edge live demonstrations
Secured 501(k) FDA clearance for the mBôs surgical system

Nasdaq Debut & Beyond

In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.

For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.

Public perception says you can't raise privately post-IPO. Monogram proved that wrong.

Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.

This was retail capital at its best: strategic, repeatable, and aligned.

One vision. Zero compromises.

This wasn't a one-time raise. It was a multi-year capital strategy.

Retail capital helped Monogram:

Go from concept to commercialization without relying on VCs
Retain ownership and control in a high-burn industry
Build a base of loyal shareholders who invested not once, but over and over again
Uplist to the Nasdaq, and still keep raising post-IPO

This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.

Ready to Raise Capital on Your Terms?

Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.

Explore Raising Capital with DealMaker